The results of human clinical trials investigating the effects of flaxseed on glucose control and insulin sensitivity are inconsistent. Objective: The present study aimed to systematically review and analyze randomized controlled trials assessing the effects of flaxseed consumption on glycemic control. Data Sources: PubMed, Medline via Ovid, SCOPUS, EMBASE, and ISI Web of Sciences databases were searched up to November 2016. Study Selection: Clinical trials in which flaxseed or its products were administered as an intervention were included. Data Extraction: The outcomes were fasting blood glucose, insulin concentration, insulin resistance (HOMA-IR), insulin sensitivity (QUIKI), and hemoglobin A1c (HbA1c). Results: A total of 25 randomized clinical trials (30 treatment arms) were included. Meta-analysis suggested a significant association between flaxseed supplementation and a reduction in blood glucose (weighted mean difference [WMD], À2.94 mg/dL; 95%CI, À5.31 to À 0.56; P ¼ 0.015), insulin levels (WMD, À7.32 pmol/L; 95%CI, À11.66 to À2.97; P ¼ 0.001), and HOMA-IR index (WMD, À0.49; 95%CI,: À0.78 to À 0.20; P ¼ 0.001) and an increase in QUIKI index (WMD, 0.019; 95%CI, 0.008-0.031; P ¼ 0.001). No significant effect on HbA1c (WMD, À0.045%; 95%CI, À0.16 to À 0.07; P ¼ 0.468) was found. In subgroup analysis, a significant reduction in blood glucose, insulin, and HOMA-IR and a significant increase in QUIKI were found only in studies using whole flaxseed but not flaxseed oil and lignan extract. Furthermore, a significant reduction was observed in insulin levels and insulin sensitivity indexes only in the subset of trials lasting !12 weeks. Conclusions: Whole flaxseed, but not flaxseed oil and lignan extract, has significant effects on improving glycemic control. Further studies are needed to determine the benefits of flaxseed on glycemic parameters.
INTRODUCTION
Flaxseed comes from the seeds of an ancient plant called Linum usitatissimum. 1 It is a complex food that is an edible oil seed/grain 2 and contains high amounts of a-linolenic acid (ALA) as a crucial n-3 fatty acid, soluble fiber, lignan, and mucilage. 2 It is a rich source of fiber, 25% of which is soluble fiber that bears beneficial effects. 3, 4 The addition of soluble fiber to a diet can delay gastric emptying and glucose absorption. Therefore, flaxseed might improve glycemic control through its soluble fiber content. 5 In addition, lignan, 1 of the 3 main phytoestrogens, is an important component of flaxseed. 6 The lignan content of flaxseed, named secoisolariciresionol diglucoside, can have some protecting effects against diabetes progression by reducing glucose concentration and delaying glucose absorption after a meal. 7, 8 Moreover, the n-3 content of flaxseed, ALA, can improve insulin sensitivity 9 and glycemic control. 10 Medicinal plants are more commonly being used to effectively treat or prevent diseases and hyperglycemia. Some long-or short-term complications of hyperglycemia can be prevented by some traditional medicinal plants, including flaxseed. 11 Flaxseed consumption is common in many countries and is considered safe and beneficial because of its antioxidative and antiinflammatory effects. [12] [13] [14] It can also improve glycemic control and prevent the dire consequences of hyperglycemia. 15 Many randomized clinical trials (RCTs) have been conducted to assess the efficacy of flaxseed or its derivatives on glycemic control and insulin sensitivity. 1, 16, 17 Some studies showed beneficial effects, 11, 18 whereas others showed no benefits. 19, 20 Among the potential reasons for the discrepancies are differences in target populations, sample sizes, durations of the interventions, and form of the flaxseed or its derivatives. Hence, it is hard to arrive at a conclusion about the efficacy of flaxseed or its derivatives on glycemic control or insulin sensitivity from these trials.
Because of the conflicting results regarding the effects of flaxseed on glycemia or insulin sensitivity, a systematic review and meta-analysis were conducted to sum the data from RCTs to draw a better conclusion. A meta-analysis was also performed to assess the effects of flaxseed on glycemic control and insulin sensitivity.
METHODS

Search strategy
The present meta-analysis was designed based on the guidelines of the PRISMA statement. To begin, PICOS criteria were defined (Table 1) . PubMed, Medline via Ovid, SCOPUS, EMBASE, and ISI Web of Sciences databases were then searched for English-language reports of relevant RCTs published until November 2016 that considered the influence of flaxseed or its products (whole or ground flaxseed, lignan supplement, and flaxseed oil), using the following medical subject headings and non-medical subject heading keywords: flax* OR flaxseed* OR "flax seed*" OR "flax-seed*" OR linseed* OR lignan* OR "Linum usitatissimum*." The search was confined to human participants. Details of the search strategy in PubMed, Medline via Ovid, SCOPUS, EMBASE, and ISI Web of Sciences databases are shown in Appendix S1 in the Supporting Information for this article available online. Moreover, the reference lists of included articles were handsearched, as were related reviews and meta-analyses. PubMed's e-mail alert service was set up to identify new articles published after the search. The protocol of the study was registered in the international prospective register of systematic reviews (PROSPERO) database (http://www.crd.york.ac.uk/PROSPERO; registration no: CRD42016043500).
Study selection
Two independent investigators (H.R.D. and R.B.B.) reviewed titles and abstracts of all identified studies to ascertain whether these studies met the inclusion criteria for this meta-analysis. Discrepancies were resolved by discussion with another investigator (M.M.S.).
Studies were chosen for analysis if they met the following criteria: 1) were RCTs with either parallel or crossover design; 2) assessed the effects of flaxseed or its derivatives (whole or ground flaxseed, flaxseed oil, and lignan supplement) on glucose control and insulin sensitivity (blood glucose, insulin levels, hemoglobin A1c (HbA1c), homeostasis model assessment-estimated insulin resistance (HOMA-IR), and quantitative insulin sensitivity check index (QUIKI) ) and data could be extracted from the article (presentation of sufficient [CIs] available at baseline and at the end of follow-up in the intervention and control group); 3) had no use of hormone replacements, fish oil, or ALA in the control group; 4) had an intervention duration of at least 2 weeks; 5) included adults older than 18 years of age; and 6) had accessible fulltext articles in English.
Studies were excluded for the following reasons: 1) the net effect of flaxseed intervention could not be extracted (if flaxseed was supplemented as an adjunct to another supplement, the control group used that supplement); 2) flaxseed consumption duration was <2 weeks; 3) non-RCT study design, including animal or observational studies with a case-control, crosssectional, or cohort design; 4) information on the baseline or follow-up body composition indices was inadequate; and 5) data from the same study was reported in another publications that was already included.
Data extraction
Inclusion-exclusion screening forms were used to identify eligible articles. After selecting the eligible articles, the RCT data were reviewed independently by 2 authors (H.R.D. and R.B.B.), and the following data were extracted using a standardized electronic form: first author's name, publication year, study location, sample size (enrollment and completion), type and dose of intervention and placebo, study design, duration of the intervention, participant's status, and other information including mean age and sex. The mean values and SDs for the outcomes of interest: at study baseline, after the intervention, and/or the change between baseline and after the intervention were also extracted. Studies with multiple arms, [21] [22] [23] [24] [25] in which the interventions were administered with different doses or different age ranges, were divided into 2 groups, and 2 treatment arms were included in the meta-analysis to avoid double counting. 26 The participants in the fish oil arms in 3 studies were excluded from the analysis, [27] [28] [29] according to the PICOS criteria. When data were reported at multiple measurements, only the values from the end of the trials were used.
Quality assessment
Assessment of risk of bias in the studies included in the analysis was performed systematically using the Cochrane quality assessment tool for RCTs, which has 7 criteria for quality assessment: random sequence generation (selection bias), allocation sequence concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective outcome reporting (reporting bias), and other potential sources of bias. The risk of bias in each study was judged to be low, high, or unclear. 30 Quantitative data synthesis and statistical analysis
The effect of flaxseed supplementation on the following outcomes was evaluated: 1) blood glucose (mg/dL); 2) insulin levels (pmol/L); (3) HbA1c; (4) HOMA-IR; and (5) QUIKI. The units of blood glucose and insulin levels were collated in milligrams per deciliter and picomole per liter, respectively. Multiplication by 18 and 6.495 was used to convert glucose units from millimoles per liter to milligrams per deciliter and to convert insulin from millionths of an international unit per milliliter or thousandths of an international unit per liter to picomoles per liters, respectively.
Effect sizes were expressed as weighted mean differences (WMDs) and 95% confidence intervals. 31 The net between-group change in serum/plasma glycemic concentrations in each study was calculated as follows: (value at end of follow-up in the treatment group À value at baseline in the treatment group) À (value at end of follow-up in the control group À value at baseline in the control group).
For single-arm crossover trials, net changes in plasma concentrations of glycemic indices were calculated by subtracting the value after control intervention from that reported after treatment. The following formula for calculating SDs of the mean difference was used:
, assuming a correlation coefficient of 0.5 as a conservative estimate for R, which ranges between 0 and 1. 26 When SD was not directly available and an SEM was reported instead of SD, the following formula was used to convert it to SD: SD ¼ SEM Â square root (n), where n was the number of participants in each group. If the outcome measures were reported in medians and ranges or 95% CIs, means and SD values were estimated using the method described by Hozo et al. 32 Plot digitizer software was used to extract the data when the outcome variable was presented only in the graphic form. Heterogeneity was assessed by Cochran's Q test (with significance set at P < 0.1) and the I 2 test for calculating the percentage of heterogeneity (I 2 value ! 50% was assumed to indicate substantial heterogeneity among the studies). The pooled effect size was calculated using a random effects model in the presence of heterogeneity; otherwise, a fixed-effects model was applied. The sensitivity analysis was done using the leave-one-out method (ie, removing a single trial each time and repeating the analysis) to assess the impact of each study on the overall effect size. 33 A predefined subgroup analysis of baseline glycemic parameters, different sources of flaxseed (whole, oil, lignan), duration of supplementation, and quality assessment using the Jadad scale was performed to assess the influence of these factors on the meta-analysis results. Random-effect meta-regression was performed using the unrestricted maximum likelihood method to evaluate the association between the overall estimate of effect size with the potential moderator variables of dose of different flaxseed source, duration of supplementation, and baseline glycemic parameters.
Any potential publication bias was detected using the funnel plot and also with Begg's rank correlation and Egger's weighted regression tests. To adjust the analysis for the effects of publication bias, the Duval and Tweedie "trim and fill" and "fail-safe N" methods were used. 34 The meta-analysis was performed using
Comprehensive Meta-Analysis (CMA) V2 software (Biostat, NJ, USA). 35 P < 0.05 was considered statistically significant.
RESULTS
Selection and characteristics of included studies
The study selection process is shown in Figure 1 . A total of 2592 reports were initially identified; after removing duplicates (n ¼ 1259), 1333 articles remained. Of the 1333 articles, 1282 were excluded because they were either not RCTs involving humans or were unrelated to the present meta-analysis according to PICOS criteria after a careful review of the titles and abstracts. Therefore, 51 potentially relevant articles were selected for full-text evaluation and detailed examination. After final assessment, a total of 25 eligible RCTs with 30 treatment arms satisfied the inclusion criteria and qualified for the meta-analysis. [20] [21] [22] [23] [24] [25] [27] [28] [29] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] Characteristics of included studies
Characteristics of the studies reported in the 25 eligible articles are presented in Table 2. 11,20-25,27-29,36-50 Data were pooled from 25 eligible studies with 30 treatment arms, which included a total of 2080 randomly assigned participants, of whom 1879 (90.33%) completed the studies. The number of participants in these individual trials ranged from 9 50 to 277. 47 The included studies were published between 1995 and 2016 and were conducted in Iran (4 studies), 23, 45, 48, 49 China (4 studies), 21, 27, 43, 47 Canada (8 studies), 22, 25, 28, 20, 36, 37, 39, 46 the United States (4 studies), 24, 29, 42, 50 Brazil (2 studies), 38, 40 Finland (1 study), 44 India (1 study), 11 and Greece (1 study). 41 The mean age of the participants ranged from 29.4 to 67.6 years. Three trials included women exclusively, 29 ,36,39 1 included men exclusively, 38 and the remaining trials included both sexes 11, [21] [22] [23] 25, 27, 28, 20, 37, [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] 51 ; for 1 study, however, the sex of participants was not reported. 50 
Data quality
The assessment of risk of bias in the included studies using Cochrane criteria is shown in Table 3 . 
Meta-analysis results
Forest plots summarizing the meta-analysis of trials on each glycemic parameter are illustrated in Figure 2A -E. The results for blood glucose were reported in 30 comparisons from 24 studies including a total of 1610 participants. Pooled results from the random-effect model showed that flaxseed consumption significantly reduced blood glucose level (WMD, À2.94 mg/dL; 95%CI, À5.31 to À0.56; P ¼ 0.02), with significant heterogeneity (I 2 ¼ 74.16%; P < 0.001) (Figure 2A ). Eighteen trials with 22 treatment arms totaling 1310 participants provided data on insulin levels. Figure 2B shows the pooled results from the fixed-effects model combing the WMD for the effect of flaxseed consumption on insulin levels in the study population, which demonstrates that the levels of insulin were significantly reduced in the flaxseed treatment groups compared with the control groups (WMD, À7.32 pmol/L; 95%CI, À11.66 to À2.97; P ¼ 0.001), with significant heterogeneity among the studies (I 2 ¼ 47.03%; P ¼ 0.008). The results for HbA1c were shown in 11 comparisons from 9 studies including 547 participants. Overall, interventions with flaxseed or its derivatives did not significantly affect HbA1c (WMD, À0.045%; 95%CI, À0.16 to À 0.07; P ¼ 0.47), with no significant heterogeneity among the studies (I 2 ¼ 32.68%; P ¼ 0.137) ( Figure 2C ).
The impact of flaxseed supplementation on HOMA-IR (13 trials, 17 treatment arms, 814 participants) and QUIKI (6 trials, 7 treatment arms, 316 participants) were also assessed. Pooled results from the random-effect model showed that flaxseed consumption significantly reduced HOMA-IR (WMD, À0.49; 95%CI, À0.78 to À 0.20; P ¼ 0.001) and QUIKI (WMD, 0.019; 95%CI, 0.008-0.031; P ¼ 0.001), with significant heterogeneity (I 2 ¼ 61.52%, P < 0.001 for HOMA-IR and 66.91%, P ¼ 0.006 for QUIKI) ( Figure 2D,E) .
Because the test for heterogeneity was statistically significant for blood glucose, insulin levels, HOMA-IR, and QUIKI, the results from random-effects models were reported, but because no significant heterogeneity was found for HbA1c, the results were reported based on fixed-effect models.
Sensitivity analysis
The effect sizes for the influence of flaxseed on insulin, HbA1c, HOMA-IR, and QUIKI were robust in the leave-one-out sensitivity analysis, suggesting the omission of each single trial did not have a significant effect on the results of meta-analysis, but the effect of flaxseed on blood glucose was sensitive to the study performed by Rhee et al. 50 Removing this study from the analysis rendered the effect of flaxseed on blood glucose nonsignificant (WMD, À1.35 mg/dL; 95%CI, À3.01 to 0.31; P ¼ 0.11) (see Figure S1 in the Supporting Information online).
Subgroup analysis
The subgroup analyses were done based on the following variables: type of flaxseed, intervention duration, and baseline glycemic control. The results are summarized in Table 4 .
When the meta-analysis was stratified according to the type of administered flaxseed supplement, a significant reduction in blood glucose was found in studies using whole flaxseed (WMD, À5.94 mg/dL; 95%CI, À10.16 to À 1.71; P ¼ 0.006), but not flaxseed oil (WMD, 1.16 mg/dL; 95%CI, À0.12 to 2.45; P ¼ 0.08) or lignan extract (WMD, À0.83 mg/dL; 95%CI, À4.81 to 3.14; P ¼ 0.68). Insulin concentrations also decreased significantly in the interventions using whole flaxseed (WMD, À7.07 pmol/L; 95%CI, À12.13 to À 1.93; P ¼ 0.007), but not flaxseed oil (WMD, À11.61 pmol/L; 95%CI, À25.79 to 2.57; P ¼ 0.11) or lignan extract (WMD, À3.73 pmol/L; 95%CI, À12.32 to 5.57; Table 2 Characteristics of studies that evaluated the effect of flaxseed consumption on glycemic control When the studies were stratified according to their duration, there was a significantly greater effect on insulin levels in the subset of trials with ! 12 weeks of duration (WMD, À5.21 pmol/L; 95%CI, À9.16 to À 1.27; P ¼ 0.01) compared with the subset lasting <12 weeks (WMD, À11.72; 95%CI, À26.65 to 3.21; P ¼ 0.12). Similarly, the effect of flaxseed on HOMA-IR was significantly greater in the subgroup with duration of intervention !12 weeks (WMD, À0.60; 95%CI, À0.91 to À 0.30; P < 0.001) compared with studies with shorter duration (WMD, 0.028; 95%CI, À0.79 to 0.84; P ¼ 0.09) ( Table 2 11,20-25,27-29,36-50 ). With respect to blood glucose, a greater but not statistically significant reduction was found in the subset of studies with !12 weeks of duration (WMD, À3.63; 95%CI, À7.77 to 0.51; P ¼ 0.09) compared wtih the subset lasting <12 weeks (WMD, À1.89; 95%CI, À4.74 to 0.94; P ¼ 0.19).
The included studies were also stratified according to the baseline glycemic status. Significant reductions were found in those studies whose participants had baseline glucose !100 mg/dL (WMD, À5.59; 95%CI, À9.98 to À 1.20; P ¼ 0.01) but not in the studies whose participants had lower initial concentrations (WMD, À0.22; 95%CI, À2.24 to 1.79; P ¼ 0.83). The same pattern was observed for HbA1c: a change of À 0.16% (95%CI, À0.31 to À 0.01; P ¼ 0.03) and a change of 0.17% (95%CI, À0.02 to 0.37; P ¼ 0.08) for the studies with high (!6%) or low (<6%) initial concentrations, respectively.
The results of subgroup analysis also suggested more pronounced reduction of insulin levels in the subset of trials with higher (!100 pmol/L) baseline insulin levels (WMD, À19.39; 95%CI, À32.72 to À 6.06; P ¼ 0.004) compared with those with lower baseline levels (WMD, À5.01; 95%CI, À9.09 to À 0.92; P ¼ 0.02).
Publication bias
Visual inspection of funnel plots suggested an asymmetry in the meta-analyses of flaxseed effects on glycemic parameters. Using the "trim and fill" method, 8, 3, 2, 1, and 2 potentially missing studies were imputed for the meta-analyses of blood glucose, insulin, HbA1c, HOMA-IR, and QUIKI, respectively ( Figure 3A-E) . Other potential threats to validity Corrected effect sizes (following imputation of potentially missing studies) and the results of Egger's linear regression, Begg's rank correlation, and "fail safe N" tests are summarized in Table S1 in the Supporting Information online.
DISCUSSION
The present meta-analysis comprehensively and systematically reviewed the currently available literature that reports on the effects of flaxseed products on glucose control and insulin sensitivity in adults. The findings demonstrated that participants receiving flaxseed products had significant improvements in blood glucose, insulin level, HOMA-IR, and QUIKI. However, glycemic measures were significantly reduced only with whole flaxseed and only when the trials lasted for 12 or more weeks. Four published meta-analyses quantify and explore the influence of flaxseed products on lipid profiles, blood pressure, and inflammatory marker C-reactive protein. 1, [53] [54] [55] However, reports of the effects of flaxseed products on glucose control and insulin sensitivity remain inconsistent, and these effects have not been systematically examined. Hence, this meta-analysis is the first to quantify the overall effects of flaxseed products on the markers of glycemic control in adults within available RCTs. The results of this meta-analysis confirmed the conclusions made by other studies regarding the effects of flaxseed consumption on blood glucose, 16, 25, 56 insulin, and HOMA-IR. 25 These effects might be due to the components of flaxseed, including soluble fiber and lignin, which can affect blood glucose control and insulin sensitivity. 15, 57 The fiber content of flaxseed might slow down glucose absorption, which can mitigate the need for insulin production. Hence, insulin secretion might decline following the ingestion of flaxseed. 25, 58 Additionally, flaxseed contains an n-3 fatty acid in the form of ALA that has positive effects on glycemic control. 15, 57 Many studies have demonstrated the effect of n-3 consumption on improving plasma glucose 59, 60 ; the effect of flaxseed consumption on plasma glucose found in this meta-analysis may be explained by the n-3 content of flaxseed. Alternatively, the improvements in insulin sensitivity following the consumption of flaxseed might be due to the antioxidant effects of flaxseed, as there is a correlation between oxidative markers and insulin sensitivity. 15 Additionally, the gum present in flaxseed acts like fiber in reducing blood glucose, 11 and it can reduce carbohydrate absorption from the gut. Another possible mechanism to explain the effects of flaxseed supplementation on insulin secretion is the stimulation of insulin secretion by flaxseed protein. 61 Moreover, the effect of flaxseed lignan on suppression of the expression of the phospho-enolpyruvate carboxykinase (PEPCK) gene has been demonstrated. This gene is responsible for glucose production through the gluconeogenesis pathway. Hence, flaxseed lignan might inhibit glucose production through suppression of gluconeogenesis and can thus help glycemic control. 62 It should be mentioned that if the study by Rhee et al 50 was to be removed from the sensitivity analysis, the results of the effects of flaxseed supplementation on plasma glucose would be changed to nonsignificant. Therefore, the results regarding the effect of flaxseed supplementation on glucose levels must be interpreted with caution.
The significant reduction in body composition indices with whole flaxseed, as opposed to other products, may be due to the high quantity of fiber (of which 25% is in a soluble form) that whole flaxseed contains. 4, 63 The glycemic-improving effect of dietary fiber has been proposed to work through different mechanisms, such as affecting gastric emptying and also reducing or delaying macronutrient absorption from the gut. 64 One of the main findings of the present metaanalysis was the reductive effect of supplementation duration on glycemic indices, as the subgroup analysis showed a significant reduction in the glycemic index in interventions with a duration !12 weeks but did not find such a reduction in interventions of a shorter duration. This means that flaxseed supplementation might not affect glycemic parameters in short-term interventions (<12 weeks), and the results are greater with long-term use of supplements. This finding is in line with the results of a study about the effects of 3 months of flaxseed lignan consumption on reducing plasma glucose and HbA1c in patients with type 2 diabetes. 36 This was also confirmed in another study in which the effects of flaxseed supplementation on blood glucose and insulin resistance was seen after 12 weeks of intervention in those with metabolic syndrome. 51 The possible explanation for these findings is a gradual increase in ALA, which can be converted to long-chain n-3 fatty acids, including eicosapentaenoic acid (EPA; 20: 5n-3) and docosahexaenoic acid (DHA; 22: 6n-3), in the body 65 and subsequently increase EPA and DHA concentrations. 66 Eicosapentaenoic acid and DHA might improve insulin sensitivity and glycemic control. [67] [68] [69] Another mechanism may be the gradual increase in intestinal gut flora following fiber consumption. 70 The relationship between increased gut flora and glycemic improvement has been shown in previous studies. 71 The effects of flaxseed supplementation on blood glucose were more pronounced in the studies whose participants had higher baseline glucose levels (>100 mg/dL). Therefore, it appears that higher blood glucose made the participants more likely to be affected by the supplementation.
The current meta-analysis has pooled the results of available RCTs regarding the effect of flaxseed on glycemic indices and presents findings that are valuable for researchers and clinicians. However, this study had several weaknesses, and the findings should be interpreted with caution. Most of the trials included small sample sizes: more than half of the included trials had a population of fewer than 50 participants, and 6 studies had fewer than 30 participants. Moreover, the significant heterogeneity among studies (different methodologies and different populations) indicated that the effects of flaxseed on glycemic indices are not uniform.
Strengths of the current meta-analysis include the relatively high number of studies included and the high quality of most of the included RCTs (n ¼ 17 of 25) according to the Jadad scale.
CONCLUSION
The results of the present systematic review and metaanalysis indicate that flaxseed supplementation may improve glycemic control. The changes may be more pronounced with whole flaxseed consumption, in populations with higher baseline glucose levels, and in interventions with longer durations (!12 weeks).
Further studies with larger sample sizes, longer durations, and the use of various types of flaxseed and its derivatives in the same participants might be necessary to confirm the efficacy of flaxseed supplementation for lowering blood glucose or improving insulin sensitivity.
